Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors
February 24 2020 - 8:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on
accelerating the development of medicines to treat cancer and other
serious diseases, today announced the appointment of Pratik S.
Multani, M.D., to its Board of Directors, effective immediately.
Dr. Multani currently serves as Chief Medical Officer of ORIC
Pharmaceuticals. He replaces Jim Daly, who recently stepped down
from the Board of Directors.
‘We are thrilled to welcome Pratik to our Board of Directors.
His significant experience advancing oncology products from the
clinic through regulatory approval will be a valuable resource as
we advance DSTAT in newly diagnosed acute myeloid leukemia
patients,” said Mike Sherman, President and Chief Executive Officer
of Chimerix. “We also thank Jim for his considerable contribution
to Chimerix over the last six years, particularly in supporting our
recent re-positioning of the company, and wish him well in all of
his future endeavors.”
“I am delighted to be joining the Chimerix Board of Directors at
this exciting stage of the company’s development. I look forward to
working with my fellow directors to guide Chimerix as we strive to
bring life-saving therapies to patients battling cancer and other
serious diseases,” said Dr. Multani.
Prior to joining ORIC, Dr. Multani served as Chief Medical
Officer of Ignyta, which was acquired by Roche in 2017. Prior to
Ignyta, Dr. Multani was Chief Medical Officer of Fate Therapeutics,
and prior to that held multiple leadership positions at Kalypsys,
Kanisa, and Salmedix. Dr. Multani started his biotech career at
Biogen Idec, where he was involved with the development of both
Zevalin and Rituxan for treatment of Non-Hodgkin Lymphoma.
Earlier in his career, Dr. Multani held academic and clinical
positions at Harvard Medical School and at Massachusetts General
Hospital. His postdoctoral training included a fellowship in
hematology and oncology at Dana-Farber Cancer Institute and an
internship and residency in Internal Medicine at Massachusetts
General Hospital. Dr. Multani received an M.D. from Harvard Medical
School and an M.S. in clinical epidemiology from Harvard School of
Public Health.
About Chimerix
Chimerix is a development-stage biopharmaceutical company
dedicated to accelerating the advancement of innovative medicines
that make a meaningful impact in the lives of patients living with
cancer and other serious diseases. The two clinical-stage
development programs are dociparstat sodium (DSTAT) and
brincidofovir (BCV).
Dociparstat sodium is a potential first-in-class
glycosaminoglycan compound derived from porcine heparin that has
low anticoagulant activity but retains the ability to inhibit
activities of several key proteins implicated in the retention and
viability of acute myeloid leukemia (AML) blasts and leukemic stem
cells in the bone marrow during chemotherapy (e.g., CXCL12,
selectins, HMGB1, elastase). Mobilization of AML blasts and
leukemic stem cells from the bone marrow has been associated with
enhanced chemosensitivity and may be a primary mechanism accounting
for the observed increases in event-free survival (EFS) and overall
survival (OS) in Phase 2 with DSTAT versus placebo. Randomized
Phase 2 data suggest that DSTAT may also accelerate platelet
recovery post-chemotherapy via inhibition of platelet factor 4, a
negative regulator of platelet production that impairs platelet
recovery following chemotherapy. BCV is an antiviral drug candidate
in development as a medical countermeasure for smallpox. For
further information, please visit the Chimerix website,
www.chimerix.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include those relating to, among other things, the
development of DSTAT in newly diagnosed acute myeloid leukemia
patients. Among the factors and risks that could cause actual
results to differ materially from those indicated in the
forward-looking statements are risks that development activities
related to DSTAT may not be completed on time or at all; risks that
ongoing or future trials may not be successful or replicate
previous trial results, or may not be predictive of real-world
results or of results in subsequent trials; risks and uncertainties
relating to competitive products and technological changes that may
limit demand for our drugs; risks that our drugs may be precluded
from commercialization by the proprietary rights of third parties;
and additional risks set forth in the Company's filings with
the Securities and Exchange Commission. These forward-looking
statements represent the Company's judgment as of the date of this
release. The Company disclaims, however, any intent or obligation
to update these forward-looking statements.
CONTACT:Investor Relations: Michelle LaSpaluto
919-972-7115ir@chimerix.com Will O’Connor Stern Investor Relations
will@sternir.com 212-362-1200
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024